Fundraising FoxSeaStar Medical Holding
NASDAQ: ICUDenver, US · Founded 2020 · Colorado corporation
Find your way into SeaStar Medical Holding
Sign up to see every warm intro you have to SeaStar Medical Holding
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SeaStar Medical Holding team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SeaStar Medical develops an extracorporeal immune-modulation device designed to reduce pathologic inflammation in critically ill patients with acute kidney injury, cardiorenal syndrome, and other serious inflammatory conditions. The company received FDA approval in 2024 for its pediatric indication and is conducting pivotal trials in adult populations while pursuing development across multiple acute and chronic disease applications.
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$10M disclosed across 1 round · 2024
▶$10MraisedJul 2024 · 4 investors · Other Health CareRule 506(b)
- Jennifer A. BairdDirector
- David GreenExecutive Officer
- John NeumanDirector
- Eric SchlorffExecutive Officer, Director
- Bernadette N. VincentDirector
- Kevin ChungExecutive Officer
- Allan CollinsDirector
- Rick BarnettDirector
- Kenneth Van HeelDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $850K
- Placement agents
- H.C. Wainwright & Co., LLC, Maxim Group LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Colorado, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does SeaStar Medical Holding do?
- SeaStar Medical develops an extracorporeal immune-modulation device designed to reduce pathologic inflammation in critically ill patients with acute kidney injury, cardiorenal syndrome, and other serious inflammatory conditions. The company received FDA approval in 2024 for its pediatric indication and is conducting pivotal trials in adult populations while pursuing development across multiple acute and chronic disease applications.
- How much funding has SeaStar Medical Holding raised?
- SeaStar Medical Holding has disclosed $10M raised across 1 round.
- Where is SeaStar Medical Holding headquartered?
- SeaStar Medical Holding is headquartered in Denver, US.